10x Genomics (TXG) Stock Looks Fully Priced As Atera Demand Lifts Guidance

10x Genomics stock has delivered a very strong 330.8% return over the past year, yet the current valuation checks lean expensive rather than pointing to an obvious bargain.

• The 330.8% gain over 12 months highlights how quickly expectations have shifted for 10x Genomics, which raises the bar for what the business now needs to deliver.
• Stronger interest in the Atera spatial biology platform and related partnerships can support higher revenue expectations, while any slowdown in that demand or integration setbacks for recent acquisitions may weigh on what investors are willing to pay.
• On Simply Wall St's broader valuation checks, 10x Genomics is judged to be undervalued on 0 of 6 tests, which suggests the stock does not screen as clearly cheap based on current fundamentals and market multiples.

The issue now is whether recent gains in 10x Genomics are already pricing in most of the good news or if there is still room for value conscious investors to see further upside.

10x Genomics delivered 330.8% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Has 10x Genomics Run Too Far on Sales?

P/S is often a useful yardstick for 10x Genomics because the business is still building towards consistent profitability, so revenue is the cleaner anchor. Right now, the stock trades on a P/S of about 12.2x, compared with roughly 4.2x for the wider Life Sciences industry and about 5.7x for its peer group. That is a sizeable premium to the sector and to companies with similar business profiles.

The fair P/S ratio for 10x Genomics, based on Simply Wall St's model that blends growth, margins, industry context and risk, is estimated at about 5.9x. This is below the current 12.2x, which indicates that investors are already paying a substantial premium for the company. Despite recent enthusiasm around the Atera platform and raised revenue guidance, the current market multiple indicates that a lot of positive developments may already be reflected in the share price.

On this P/S multiple, 10x Genomics stock appears overvalued relative to what the fundamentals currently support.

See what the numbers say about this price — find out in our valuation breakdown.

The 10x Genomics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives are the link between 10x Genomics' current valuation and what would need to happen next on growth, margins and earnings for the stock to be worth materially more or less than today’s price. They sit on the company’s Community page. Rather than relying on a single multiple or model output, each one spells out its underlying assumptions so you can compare them with the actual results as they are reported.

One of the top community narratives on 10x Genomics: 40% overvalued

"Product transitions to lower cost solutions, while driving higher reaction volumes, are creating a near term headwind to consumables revenue growth…"

Read one of the top narratives on 10x Genomics

Do you think there's more to the story for 10x Genomics? Head over to our Community to see what others are saying!

The Bottom Line

For 10x Genomics, the key takeaway is that the current market multiple points to an overvalued stock rather than an obvious value opportunity. The premium to industry P/S levels means expectations are already set high, so future returns will depend less on multiple expansion and more on how the business delivers against those expectations. With a low value score, the burden of proof now sits with revenue growth, margin progression and execution on Atera and recent acquisitions. The core question from here is whether the company can sustain enough quality growth to justify staying on this premium valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com